Aspen is to pay £700m for GlaxoSmithKline’s off-patent blood clotting medicines; Arixtra and Fraxiparine including control of its factory in France. GSK will retain control of some markets in Asia for these two products.
Aspen is to pay £700m for GlaxoSmithKline’s off-patent blood clotting medicines; Arixtra and Fraxiparine including control of its factory in France. GSK will retain control of some markets in Asia for these two products.
© 2023 Fortissa. All rights reserved. Privacy Statement | Terms & Conditions